hsa-miR-144-3p

ncRNA information

ncRNA name

hsa-miR-144-3p

Specific or universal ncRNAs

Universal ncRNAs

Class

MicroRNA

Biomarker

Yes

Biomarker application

Treatment

Upstream regulatory factors

Not available

Downstream target

ARID1A

Cancer information

Cancer name

Renal Cell Carcinoma

Cancer site

Kidney

Treatment information

Treatment type

Chemotherapy

Drug

Sunitinib

Impact of wild-type ncRNA on chemotherapy resistance

Impact of knockdown of ncRNA on chemotherapy resistance

Impact of overexpression of ncRNA on chemotherapy resistance

Up

Clinical Information

ncRNA differential expression in
cancer patients vs. healthy people

Not available

Number of patients

Not available

Male patients

Not available

Female patients

Not available

Age range and number

Not available

Research information

PMID

Description

Higher miR-144-3p may enhance malignancy and resistance to Sunitinib in ccRCC by targeting ARID1A, the observations may uncover novel strategies of ccRCC treatment.

Tissue resource

renal cell carcinoma tumor tissues

human renal cell carcinoma cell lines 786-O

human renal cell carcinoma cell lines SN12-PM6

Experiment

qRT-PCR,Western blot,Luciferase reporter assay


Institute

Union hospital, Tongji Medical College

American Type Culture Collection

MD Anderson Cancer Center

Country

China

USA

Continent

Asia

North American